ADVM:NSD-Adverum Biotechnologies, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 9.77

Change

-1.22 (-11.10)%

Market Cap

USD 0.91B

Volume

1.45M

Average Target Price

USD 18.50 (+89.36%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+6.03 (+2.60%)

USD61.69B 52.76 43.54
REGN Regeneron Pharmaceuticals, Inc

+15.29 (+3.23%)

USD52.04B 25.62 18.92
SGEN Seattle Genetics, Inc

+0.09 (+0.08%)

USD18.82B N/A -91.93
ALXN Alexion Pharmaceuticals, Inc

+2.53 (+2.90%)

USD18.60B 7.85 7.48
INCY Incyte Corporation

+1.06 (+1.47%)

USD14.95B 33.64 27.08
BMRN BioMarin Pharmaceutical Inc

+2.01 (+2.44%)

USD14.84B N/A 31,783.95
GMAB Genmab A/S

+0.71 (+3.47%)

USD12.83B N/A N/A
BNTX BioNTech SE

-3.60 (-5.81%)

USD12.47B N/A N/A
ALNY Alnylam Pharmaceuticals, Inc

+0.02 (+0.02%)

USD11.78B N/A -11.75
GLPG Galapagos NV

+5.54 (+2.91%)

USD11.64B 72.40 N/A

ETFs Containing ADVM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.19% 65% D 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.19% 65% D 70% C-
Trailing 12 Months  
Capital Gain 80.59% 90% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.59% 90% A- 95% A
Trailing 5 Years  
Capital Gain -74.99% 40% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.99% 39% F 18% F
Average Annual (5 Year Horizon)  
Capital Gain 30.14% 72% C- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.14% 71% C- 71% C-
Risk Return Profile  
Volatility (Standard Deviation) 94.92% 20% F 9% F
Risk Adjusted Return 31.75% 64% D 42% F
Market Capitalization 0.91B 80% B- 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.40 33% F 21% F
Price / Cash Flow Ratio -18.52 86% B 90% A-
EV/EBITDA -11.60 86% B 88% B+
Management Effectiveness  
Return on Equity -34.29% 79% C+ 28% F
Return on Invested Capital -36.40% 71% C- 23% F
Return on Assets -19.64% 72% C- 22% F
Debt to Equity Ratio 0.06% 83% B 90% A-
Technical Ratios  
Short Ratio 6.61 29% F 19% F
Short Percent 18.80% 15% F 15% F
Beta 2.29 20% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector